Clinical Trials
11 trialsNCT05020236 2026-05-05
MAGNETISMM-5
Pfizer
Phase 3 Recruiting
NCT06484777 2026-04-16
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT06574568 2026-02-05
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd
Phase 1 Recruiting
NCT06049290 2025-12-04
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT06425276 2024-05-23
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
CASI Pharmaceuticals (China) Co., Ltd.
Phase 4 Completed
NCT06082596 2023-10-13
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
BeBetter Med Inc
Phase 1 Completed
NCT05052970 2022-02-01
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 1 Unknown
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT01660633 2020-04-21
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
Acrotech Biopharma Inc.
Phase 2 Completed
NCT00925782 2019-12-17
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
Acrotech Biopharma Inc.
Phase 2 Completed
NCT01148108 2013-03-15
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Telik
Phase 2 Completed